SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. __)*
Agile Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
00847L 10 0
(CUSIP Number)
Pasquale DeAngelis
ProQuest Investments
2430 Vanderbilt Beach Road, #108 - 190
Naples, FL 34109
(609) 919-3567
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
May 29, 2014
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No. 00847L 10 0
|
13D
|
Page 2 of 14 Pages
|
|
1.
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
ProQuest Investments III, L.P. 20-0992411
|
||||
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
o
|
||
|
(b)
|
x
|
||||
|
3.
|
SEC USE ONLY
|
||||
|
4.
|
SOURCE OF FUNDS
WC
|
||||
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
o
|
|||
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
||||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER
0
|
|||
|
8.
|
SHARED VOTING POWER
2,677,846
|
||||
|
9.
|
SOLE DISPOSITIVE POWER
0
|
||||
|
10.
|
SHARED DISPOSITIVE POWER
2,677,846
|
||||
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,677,846
|
||||
|
12.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
o
|
|||
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
14.4%
|
||||
|
14.
|
TYPE OF REPORTING PERSON
PN
|
||||
|
CUSIP No. 00847L 10 0
|
13D
|
Page 3 of 14 Pages
|
|
1.
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
ProQuest Associates III LLC 20-0992451
|
||||
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
o
|
||
|
(b)
|
x
|
||||
|
3.
|
SEC USE ONLY
|
||||
|
4.
|
SOURCE OF FUNDS
AF
|
||||
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
o
|
|||
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
||||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER
0
|
|||
|
8.
|
SHARED VOTING POWER
2,677,846
|
||||
|
9.
|
SOLE DISPOSITIVE POWER
0
|
||||
|
10.
|
SHARED DISPOSITIVE POWER
2,677,846
|
||||
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,677,846
|
||||
|
12.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
o
|
|||
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
14.4%
|
||||
|
14.
|
TYPE OF REPORTING PERSON
OO
|
||||
|
CUSIP No. 00847L 10 0
|
13D
|
Page 4 of 14 Pages
|
|
1.
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
ProQuest Investments IV, L.P. 20-5935001
|
||||
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
o
|
||
|
(b)
|
x
|
||||
|
3.
|
SEC USE ONLY
|
||||
|
4.
|
SOURCE OF FUNDS
WC
|
||||
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
o
|
|||
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
||||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER
0
|
|||
|
8.
|
SHARED VOTING POWER
1,178,851
|
||||
|
9.
|
SOLE DISPOSITIVE POWER
0
|
||||
|
10.
|
SHARED DISPOSITIVE POWER
1,178,851
|
||||
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,178,851
|
||||
|
12.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
o
|
|||
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.3%
|
||||
|
14.
|
TYPE OF REPORTING PERSON
PN
|
||||
|
CUSIP No. 00847L 10 0
|
13D
|
Page 5 of 14 Pages
|
|
1.
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
ProQuest Associates IV LLC 20-5934968
|
||||
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
o
|
||
|
(b)
|
x
|
||||
|
3.
|
SEC USE ONLY
|
||||
|
4.
|
SOURCE OF FUNDS
AF
|
||||
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
o
|
|||
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
||||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER
0
|
|||
|
8.
|
SHARED VOTING POWER
1,178,851
|
||||
|
9.
|
SOLE DISPOSITIVE POWER
0
|
||||
|
10.
|
SHARED DISPOSITIVE POWER
1,178,851
|
||||
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,178,851
|
||||
|
12.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
o
|
|||
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.3%
|
||||
|
14.
|
TYPE OF REPORTING PERSON
OO
|
||||
|
CUSIP No. 00847L 10 0
|
13D
|
Page 6 of 14 Pages
|
|
1.
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Jay Moorin
|
||||
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
o
|
||
|
(b)
|
x
|
||||
|
3.
|
SEC USE ONLY
|
||||
|
4.
|
SOURCE OF FUNDS
AF
|
||||
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
o
|
|||
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
||||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER
0
|
|||
|
8.
|
SHARED VOTING POWER
3,856,697
|
||||
|
9.
|
SOLE DISPOSITIVE POWER
0
|
||||
|
10.
|
SHARED DISPOSITIVE POWER
3,856,697
|
||||
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,856,697
|
||||
|
12.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
o
|
|||
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
20.7%
|
||||
|
14.
|
TYPE OF REPORTING PERSON
IN
|
||||
|
CUSIP No. 00847L 10 0
|
13D
|
Page 7 of 14 Pages
|
|
1.
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Alain Schreiber
|
||||
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
o
|
||
|
(b)
|
x
|
||||
|
3.
|
SEC USE ONLY
|
||||
|
4.
|
SOURCE OF FUNDS
AF
|
||||
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
|
o
|
|||
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States Resident Alien
|
||||
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER
0
|
|||
|
8.
|
SHARED VOTING POWER
3,856,697
|
||||
|
9.
|
SOLE DISPOSITIVE POWER
0
|
||||
|
10.
|
SHARED DISPOSITIVE POWER
3,856,697
|
||||
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,856,697
|
||||
|
12.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
o
|
|||
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
20.7%
|
||||
|
14.
|
TYPE OF REPORTING PERSON
IN
|
||||
.
|
CUSIP No. 00847L 10 0
|
13D
|
Page 8 of 14 Pages
|
Introduction.
Item 1. Security and Issuer.
This Schedule 13D relates to Common Stock, par value $0.0001 per share (the “Common Stock”), issued by Agile Therapeutics, Inc. (the “Issuer”). The Issuer’s principal executive office is located at 101 Poor Farm Road, Princeton, New Jersey 08540.
Item 2. Identity and Background.
|
(a)-(c)
|
ProQuest Investments III, L.P. (“Investments III”) is a Delaware limited partnership with its principal office located at 2430 Vanderbilt Beach Road, #108-190, Naples, Florida 34109.
|
|
|
ProQuest Associates III LLC (“Associates III”) is a Delaware limited liability company and the general partner of Investments III, with its principal office located at 2430 Vanderbilt Beach Road, #108-190, Naples, Florida 34109.
|
||
|
ProQuest Investments IV, L.P. (“Investments IV”) is a Delaware limited partnership with its principal office located at 2430 Vanderbilt Beach Road, #108-190, Naples, Florida 34109.
|
||
|
ProQuest Associates IV LLC (“Associates IV”) is a Delaware limited liability company and the general partner of Investments IV, with its principal office located at 2430 Vanderbilt Beach Road, #108-190, Naples, Florida 34109.
|
||
|
Jay Moorin (“Moorin”) is an individual and Managing Member of Associates II and Associates III. The principal business address for Jay Moorin is c/o ProQuest Investments, 2430 Vanderbilt Beach Road, #108-190, Naples, Florida 34109.
|
||
|
Alain Schreiber (“Schreiber”) is an individual and Managing Member of Associates II and Associates III. The principal business address for Alain Schreiber is c/o ProQuest Investments, 2430 Vanderbilt Beach Road, #108-190, Naples, Florida 34109.
|
||
|
Investments III, Associates III, Investments IV, Associates IV, Moorin and Schreiber are referred to as the Reporting Persons.
|
||
|
(d)
|
During the last five years, none of Investments III, Associates III, Investments IV, Associates IV, Moorin or Schreiber have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
|
|
|
CUSIP No. 00847L 10 0
|
13D
|
Page 9 of 14 Pages
|
|
(e)
|
During the last five years, none of Investments III, Associates III, Investments IV, Associates IV, Moorin or Schreiber have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
|
|
|
(f)
|
Investments III and Investments IV are Delaware limited partnerships. Associates III and Associates IV are Delaware limited liability companies. Moorin is a United States citizen. Schreiber is a United States resident alien.
|
|
Item 3. Source and Amount of Funds or Other Consideration.
|
On May 29, 2014, the Issuer consummated its initial public offering of Common Stock (the “IPO). Immediately prior to the IPO, the Reporting Persons had beneficially owned the following securities of the Issuer: (a) Investments III directly and Associates III indirectly beneficially owned (i) 2,723 shares of Common Stock, (ii) 117,441 shares of Series A-1 preferred stock, (iii) 1,000,000 shares of Series B preferred stock, (iv) 236,061 shares of Series C preferred stock, (v) warrants to purchase 141,825 shares of Series A-1 preferred stock and (vi) notes in the principal amount of $676,652.12 that were convertible into Common Stock and (b) Investments IV directly and Associates IV indirectly beneficially owned (i) 393,000 shares of Series B preferred stock, (ii) 92,760 shares of Series C preferred stock and (iii) notes in the principal amount of $265,888.72 that were convertible into Common Stock. Messrs. Moorin and Schreiber were deemed to beneficially own all of such securities. Upon the closing of the IPO, (i) all of the shares of Series A-1, Series B and Series C preferred stock automatically converted to Common Stock on a 1.4-for-1 basis, (ii) the warrants expired unexercised and (iii) the notes converted to Common Stock at a conversion price of $6.00. On May 29, 2014, Investments III and Investments IV purchased 666,667 and 454,166 shares of Common Stock, respectively, in the IPO at a price of $6 per share (the “IPO Shares”). As a result, immediately after the IPO, the Reporting Persons beneficially owned the following securities of the Issuer: (a) Investments III directly and Associates III indirectly beneficially owned 2,677,846 shares of Common Stock and (b) Investments IV directly and Associates IV indirectly beneficially owned 1,178,851 shares of Common Stock. Messrs. Moorin and Schreiber were deemed to beneficially own all 3,856,697 shares of Common Stock owned by the other Reporting Persons. All of such acquisitions were financed by working capital. Other than the IPO Shares, all shares of Common Stock acquired upon the IPO on May 29, 2014 were received upon conversion of previously owned securities.
|
Item 4. Purpose of Transaction.
|
The Reporting Persons do not at the present time have any plans or proposals which relate to or would result in:
|
(a)
|
The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer, except the acquisition of Common Stock that may be acquired by, directly or upon the exercise of stock options granted to, an affiliate of the Reporting Persons as compensation for service as a member of
|
|
CUSIP No. 00847L 10 0
|
13D
|
Page 10 of 14 Pages
|
|
|
the Issuer’s board of directors;
|
|
|
(b)
|
An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;
|
|
(c)
|
A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;
|
|
|
(d)
|
Any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the Board;
|
|
|
(e)
|
Any material change in the present capitalization or dividend policy of the Issuer;
|
|
|
(f)
|
Any other material change in the Issuer’s business or corporate structure;
|
|
|
(g)
|
Changes in the Issuer’s Certificate of Incorporation, by-laws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;
|
|
|
(h)
|
Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;
|
|
|
(i)
|
A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or
|
|
|
(j)
|
Any action similar to any of those enumerated above.
|
|
Item 5. Interest in Securities of the Issuer.
|
(a)-(b) As of the date hereof and as more fully described in Item 3 above, the Reporting Persons may be deemed to be the direct and indirect beneficial owners of an aggregate of 3,856,697 shares of Common Stock over all of which securities they have shared voting and shared dispositive power.
The 3,856,697 shares of Common Stock beneficially owned by the Reporting Persons represent 20.7% of the issued and outstanding shares of Common Stock based on 18,592,059 shares of Common Stock outstanding as of May 29, 2014 as set forth by the Issuer in its final prospectus dated May 22, 2014 and filed with the SEC on May 23, 2014. Of such 3,856,697 shares, 2,677,846, or 14.4%, are beneficially owned by each of Investments III and Associates III; 1,178,851 or 6.3%, are beneficially owned by each of Investments IV and Associates IV; and 3,856,697, or 20.7%, are beneficially owned by each of Moorin and Schreiber.
(c) Except as set forth below, there have been no transaction in the securities of the Issuer by any of the Reporting Persons during the past sixty days:
|
Date
|
Reporting
Person |
Security
|
Amount Acquired
(Disposed) |
Price
|
|
4/28/14
|
Investments III
|
Convertible Notes
|
$676,652.12
|
$676,652.12
|
|
4/28/14
|
Investments IV
|
Convertible Notes
|
$265,888.72
|
$265,888.72
|
|
CUSIP No. 00847L 10 0
|
13D
|
Page 11 of 14 Pages
|
|
Date
|
Reporting
Person |
Security
|
Amount Acquired
(Disposed) |
Price
|
|
5/29/14
|
Investments III
|
Series A-1 Preferred Stock
|
(17,441)
|
Converted*
|
| 5/29/14 |
Investments III
|
Series B Preferred Stock
|
(1,000,000)
|
Converted* |
|
5/29/14
|
Investments IV
|
Series B Preferred Stock
|
(393,000)
|
Converted*
|
|
5/29/14
|
Investments III
|
Series C Preferred Stock
|
(236,061)
|
Converted*
|
|
5/29/14
|
Investments IV
|
Series C Preferred Stock
|
(92,760)
|
Converted*
|
|
5/29/14
|
Investments III
|
Warrants to purchase Series A-1 Preferred Stock
|
(141,825)
|
Expired
|
|
5/29/14
|
Investments III
|
Convertible Notes
|
($676,652.12)
|
Converted at $6.00
|
|
5/29/14
|
Investments IV
|
Convertible Notes
|
($265,888.72)
|
Converted at $6.00
|
|
5/29/14
|
Investments III
|
Common Stock
|
2,008,456
|
Acquired upon conversions of Series A-1, B and C preferred stock and convertible note
|
|
5/29/14
|
Investments IV
|
Common Stock
|
724,685
|
Acquired upon conversions of Series B and C preferred stock and convertible note
|
|
5/29/14
|
Investments III
|
Common Stock
|
666,667 shares
|
$6.00 per share
|
|
5/29/14
|
Investments IV
|
Common Stock
|
454,166 shares
|
$6.00 per share
|
|
*Converted to Common Stock on a 1.4-for-1 shares basis.
|
|
CUSIP No. 00847L 10 0
|
13D
|
Page 12 of 14 Pages
|
|
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
|
Prior to the IPO, the Reporting Persons had been party to a stockholders agreement pursuant to which they were entitled to designate one member of the Issuer’s board of directors. Upon the closing of the IPO, the stockholders agreement terminated and the Reporting Persons no longer have any special rights regarding the election or designation of members of the Issuer's board of directors. However, one current member of the board of directors, Karen Hong, is a member of Associates III and Associates IV and was, prior to the IPO, the designee of the Reporting Persons. Any securities of the Issuer that Dr. Hong receives as compensation for her board service will be transferred or assigned to an affiliate of the Reporting Persons in accordance with the Reporting Persons’ internal policies. There are currently no such securities beneficially owned.
Investments III and Investments IV are party to a registration rights agreement with the Issuer pursuant to which they are entitled to certain demand and piggyback registration rights with respect to the Common Stock beneficially owned by them.
|
Item 7. Material to be Filed as Exhibits.
|
|
Exhibit No.
|
Description
|
|
|
4.1
|
Fifth Amended and Restated Registration Rights Agreement, dated as of July 18, 2012, by and among the Issuer and the parties listed therein, as modified by the Amendment to Registration Rights Agreement, dated as of May 5, 2014, by and among the Issuer and the parties listed therein (incorporated by reference to Exhibit 4.2 of the Registration Statement on Form S-1/A No. 3 filed by the Issuer on May 9, 2014 (File No. 333-194621)).
|
|
|
24.1
|
Power of Attorney.
|
|
|
99.1
|
Joint Filing Agreement, dated June 2, 2014, between ProQuest Investments III, L.P., ProQuest Associates III LLC, ProQuest Investments IV, L.P., ProQuest Associates IV LLC, Jay Moorin and Alain Schreiber relating to the filing of a joint statement on Schedule 13D.
|
|
CUSIP No. 00847L 10 0
|
13D
|
Page 13 of 14 Pages
|
SIGNATURES
After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certify that the information set forth in this statement is true, complete and correct.
|
DATED: June 2, 2014
|
|||
| /s/ Pasquale DeAngelis | |||
|
Pasquale DeAngelis, as a member of ProQuest Associates III LLC and on behalf of ProQuest Investments III, L.P., and as a member of ProQuest Associates IV LLC and on behalf of ProQuest Investments IV, L.P.
|
|||
|
*
|
|||
|
Jay Moorin, individually
|
|||
|
*
|
|||
|
Alain Schreiber, individually
|
|
*By:
|
/s/ Pasquale DeAngelis | |||
|
Pasquale DeAngelis, Attorney-in-Fact
|
||||
|
CUSIP No. 00847L 10 0
|
13D
|
Page 14 of 14 Pages
|
|
Exhibit Index
|
|
Exhibit No.
|
Description
|
|
|
4.1
|
Fifth Amended and Restated Registration Rights Agreement, dated as of July 18, 2012, by and among the Issuer and the parties listed therein, as modified by the Amendment to Registration Rights Agreement, dated as of May 5, 2014, by and among the Issuer and the parties listed therein (incorporated by reference to Exhibit 4.2 of the Registration Statement on Form S-1/A No. 3 filed by the Issuer on May 9, 2014 (File No. 333-194621)).
|
|
|
24.1
|
Power of Attorney.
|
|
|
99.1
|
Joint Filing Agreement, dated June 2, 2014, between ProQuest Investments III, L.P., ProQuest Associates III LLC, ProQuest Investments IV, L.P., ProQuest Associates IV LLC, Jay Moorin and Alain Schreiber relating to the filing of a joint statement on Schedule 13D.
|
EXHIBIT 24.1
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned hereby constitutes and appoints, as of the date hereof, Pasquale DeAngelis, his or her true and lawful attorney-in-fact with full power of substitution, resubstitution and revocation, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, including, but not limited to, the undersigned's individual capacity, to execute all agreements, certificates, forms, instruments, or other documents, and to take any action, necessary to file beneficial ownership reports on Schedules 13D and 13G and Forms 3, 4 and 5 (including any amendments thereto, and including any beneficial ownership reports which may in the future be required by the Securities and Exchange Commission to be filed provided that the purpose and form of such reports is substantially similar to Schedules 13D or 13G or Form 3, 4 or 5) under the Securities Exchange Act of 1934 with the Securities and Exchange Commission or any stock exchange or similar authority, in connection with any equity investments in Agile Therapeutics, Inc. by each of the undersigned in his or her individual capacity.
In connection with the appointment of such attorney-in-fact, each of the undersigned hereby grants unto said attorney-in-fact full power and authority to do and perform each and every act and thing which, in the opinion of such attorney-in-fact, may be requisite, necessary, proper or of benefit to be done in and about the premises, as fully to all intents and purposes as the undersigned might or could do in person, thereby ratifying and confirming all that said attorney-in-fact (or attorney-in-fact's substitute or substitutes), may lawfully do or cause to be done by virtue hereof, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his own discretion. Each of the undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigneds’ responsibilities to comply with Section 13 or Section 16 of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until each of the undersigned is no longer required to file Forms 3, 4 and 5 or Schedules 13D or 13G with respect to the undersigned’s holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.
|
Dated: May 20, 2014
|
|||
|
/s/ Jay Moorin
|
|||
|
Jay Moorin
|
|||
|
/s/ Alain Schreiber
|
|||
|
Alain Schreiber
|
EXHIBIT 99.1
JOINT FILING AGREEMENT
The undersigned hereby agree that the statement on Schedule 13D with respect to the shares of common stock of Agile Therapeutics, Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended. The undersigned hereby further agree that this Joint Filing Agreement be included as an exhibit to such statement and any such amendment. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
|
Dated: June 2, 2014
|
|||
| /s/ Pasquale DeAngelis | |||
|
Pasquale DeAngelis, as a member of ProQuest Associates III LLC and on behalf of ProQuest Investments III, L.P. and as a member of ProQuest Associates IV LLC and on behalf of ProQuest Investments IV, L.P.
|
|||
|
*
|
|||
|
Jay Moorin, individually
|
|||
|
*
|
|||
|
Alain Schreiber, individually
|
|
*By:
|
/s/ Pasquale DeAngelis | |
|
Pasquale DeAngelis, Attorney-in-Fact
Power of attorney filed as an exhibit hereto
|